GlaxoSmithKline Pharmaceuticals Limited CC-Dec24.pdf · 2025-02-14
Hi, good evening. Just one question. T wo questions in fact, one was a clarification. Juby, you mentioned Rs. 9 crores of one -off in the employee cost. So, is it lower or is it a negative provision which has resulted in a lower employee cost or is it a higher provision which we have taken? Just one clarification for this quarter number?
Okay and secondly on the other expenses , now as we are preparing for these new launches and also building the market for Shingrix. One on Shingrix, incrementally when we say the growth is around 15% for the total portfolio , are we finding a little difficult in terms of bringing conversion for patients on the Shingrix platform or which is resulting in a higher spending year-on-year or is it incremental investment for preparing for the new product launches which we are planning?